Altamira Therapeutics Ltd. CYTOF
0.07
0.00
0.00%
as of 24 Sep
- Market cap
- $1.1M
- P/E
- 0.0×
Follow CYTOF
| Jun '25 | Jun '24 | Jun '23 | Jun '22 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | (385.74%) | (514.91%) |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | (214.75%) | (236.82%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 807.49% | 426.90% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (6.99) | (38.84) | |
Free Cash Flow |
(19.09) | (27.16) | (29.37) | (30.09) | |
Capital Expenditures |
— | — | — | (5.68) | |
Piotroski F-Score |
— | — | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(423.46%) | (408.62%) | (1,722.06%) | (176.11%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 2.37 | 1.86 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 192.55 | 313.21 | |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | |
Tax Rate |
— | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.00 | 0.00 | 0.90 | 0.74 | |
Depreciation/Fixed assets |
2.60 | 0.00 | 0.00 | 0.29 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (36.63) | |
Revenue per Share |
— | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | (6.99) | (31.50) | |
Capex per Share |
— | — | 0.00 | (7.34) | |
Capex to Sales |
— | — | — | 0.00 | |
Net Profit Margin |
— | — | 0.00% | 0.00% |
Columns are period end dates